Global Non-Cancerous Skin Diseases Therapeutics Market 2024-2028

The non-tumorous skin diseases therapeutics market is forecasted to grow by USD 25.22 bn during 2023-2028, accelerating at a CAGR of 9.88% during the forecast period. The report on the non-tumorous skin diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	8.95%
CAGR	9.88%
Incremental Value	$25.22bn

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of skin diseases, strong pipeline landscape in non-cancerous skin diseases therapeutics, and growing demand for personalized non-cancerous skin diseases therapeutics.

Technavio's non-tumorous skin diseases therapeutics market is segmented as below:

By Therapy Area

Psoriasis
Eczema
Acne vulgaris
Others

By Route Of Administration

Injectable
Oral
Topical

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increased focus on microbiome and skin barrier as one of the prime reasons driving the non-tumorous skin diseases therapeutics market growth during the next few years. Also, misdiagnosis of skin diseases and increasing healthcare expenditure will lead to sizable demand in the market.

The report on the non-tumorous skin diseases therapeutics market covers the following areas:

Non-tumorous skin diseases therapeutics market sizing
Non-tumorous skin diseases therapeutics market forecast
Non-tumorous skin diseases therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-tumorous skin diseases therapeutics market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Incyte Corp., LEO Pharma AS, Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., UCB SA, Viatris Inc., and XBiotech Inc.. Also, the non-tumorous skin diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR40772

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Therapy Area
Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global non-cancerous skin diseases therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global non-cancerous skin diseases therapeutics market 2018 - 2022 ($ billion)
4.2 Therapy area Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Therapy area Segment 2018 - 2022 ($ billion)
4.3 Route of Administration Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Therapy Area

6.1 Market segments
Exhibit 30: Chart on Therapy Area - Market share 2023-2028 (%)
Exhibit 31: Data Table on Therapy Area - Market share 2023-2028 (%)
6.2 Comparison by Therapy Area
Exhibit 32: Chart on Comparison by Therapy Area
Exhibit 33: Data Table on Comparison by Therapy Area
6.3 Psoriasis - Market size and forecast 2023-2028
Exhibit 34: Chart on Psoriasis - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Psoriasis - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Psoriasis - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Psoriasis - Year-over-year growth 2023-2028 (%)
6.4 Eczema - Market size and forecast 2023-2028
Exhibit 38: Chart on Eczema - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Eczema - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Eczema - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Eczema - Year-over-year growth 2023-2028 (%)
6.5 Acne vulgaris - Market size and forecast 2023-2028
Exhibit 42: Chart on Acne vulgaris - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Acne vulgaris - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Acne vulgaris - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Acne vulgaris - Year-over-year growth 2023-2028 (%)
6.6 Others - Market size and forecast 2023-2028
Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.7 Market opportunity by Therapy Area
Exhibit 50: Market opportunity by Therapy Area ($ billion)
Exhibit 51: Data Table on Market opportunity by Therapy Area ($ billion)

7 Market Segmentation by Route of Administration

7.1 Market segments
Exhibit 52: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 53: Data Table on Route of Administration - Market share 2023-2028 (%)
7.2 Comparison by Route of Administration
Exhibit 54: Chart on Comparison by Route of Administration
Exhibit 55: Data Table on Comparison by Route of Administration
7.3 Injectable - Market size and forecast 2023-2028
Exhibit 56: Chart on Injectable - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Injectable - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Injectable - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Injectable - Year-over-year growth 2023-2028 (%)
7.4 Oral - Market size and forecast 2023-2028
Exhibit 60: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Oral - Year-over-year growth 2023-2028 (%)
7.5 Topical - Market size and forecast 2023-2028
Exhibit 64: Chart on Topical - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Data Table on Topical - Market size and forecast 2023-2028 ($ billion)
Exhibit 66: Chart on Topical - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Topical - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Route of Administration
Exhibit 68: Market opportunity by Route of Administration ($ billion)
Exhibit 69: Data Table on Market opportunity by Route of Administration ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 Canada - Market size and forecast 2023-2028
Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.11 China - Market size and forecast 2023-2028
Exhibit 107: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 108: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 109: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on China - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ billion)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 119: AbbVie Inc. - Overview
Exhibit 120: AbbVie Inc. - Product / Service
Exhibit 121: AbbVie Inc. - Key news
Exhibit 122: AbbVie Inc. - Key offerings
12.4 Amgen Inc.
Exhibit 123: Amgen Inc. - Overview
Exhibit 124: Amgen Inc. - Product / Service
Exhibit 125: Amgen Inc. - Key offerings
12.5 AstraZeneca Plc
Exhibit 126: AstraZeneca Plc - Overview
Exhibit 127: AstraZeneca Plc - Product / Service
Exhibit 128: AstraZeneca Plc - Key news
Exhibit 129: AstraZeneca Plc - Key offerings
12.6 Bayer AG
Exhibit 130: Bayer AG - Overview
Exhibit 131: Bayer AG - Business segments
Exhibit 132: Bayer AG - Key news
Exhibit 133: Bayer AG - Key offerings
Exhibit 134: Bayer AG - Segment focus
12.7 Bristol Myers Squibb Co.
Exhibit 135: Bristol Myers Squibb Co. - Overview
Exhibit 136: Bristol Myers Squibb Co. - Product / Service
Exhibit 137: Bristol Myers Squibb Co. - Key news
Exhibit 138: Bristol Myers Squibb Co. - Key offerings
12.8 Eli Lilly and Co.
Exhibit 139: Eli Lilly and Co. - Overview
Exhibit 140: Eli Lilly and Co. - Product / Service
Exhibit 141: Eli Lilly and Co. - Key news
Exhibit 142: Eli Lilly and Co. - Key offerings
12.9 F. Hoffmann La Roche Ltd.
Exhibit 143: F. Hoffmann La Roche Ltd. - Overview
Exhibit 144: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 145: F. Hoffmann La Roche Ltd. - Key news
Exhibit 146: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 147: F. Hoffmann La Roche Ltd. - Segment focus
12.10 Galderma SA
Exhibit 148: Galderma SA - Overview
Exhibit 149: Galderma SA - Product / Service
Exhibit 150: Galderma SA - Key news
Exhibit 151: Galderma SA - Key offerings
12.11 GlaxoSmithKline Plc
Exhibit 152: GlaxoSmithKline Plc - Overview
Exhibit 153: GlaxoSmithKline Plc - Business segments
Exhibit 154: GlaxoSmithKline Plc - Key news
Exhibit 155: GlaxoSmithKline Plc - Key offerings
Exhibit 156: GlaxoSmithKline Plc - Segment focus
12.12 LEO Pharma AS
Exhibit 157: LEO Pharma AS - Overview
Exhibit 158: LEO Pharma AS - Business segments
Exhibit 159: LEO Pharma AS - Key offerings
Exhibit 160: LEO Pharma AS - Segment focus
12.13 Merck KGaA
Exhibit 161: Merck KGaA - Overview
Exhibit 162: Merck KGaA - Business segments
Exhibit 163: Merck KGaA - Key news
Exhibit 164: Merck KGaA - Key offerings
Exhibit 165: Merck KGaA - Segment focus
12.14 Novartis AG
Exhibit 166: Novartis AG - Overview
Exhibit 167: Novartis AG - Business segments
Exhibit 168: Novartis AG - Key offerings
Exhibit 169: Novartis AG - Segment focus
12.15 Pfizer Inc.
Exhibit 170: Pfizer Inc. - Overview
Exhibit 171: Pfizer Inc. - Product / Service
Exhibit 172: Pfizer Inc. - Key news
Exhibit 173: Pfizer Inc. - Key offerings
12.16 Sanofi SA
Exhibit 174: Sanofi SA - Overview
Exhibit 175: Sanofi SA - Business segments
Exhibit 176: Sanofi SA - Key news
Exhibit 177: Sanofi SA - Key offerings
Exhibit 178: Sanofi SA - Segment focus
12.17 Sun Pharmaceutical Industries Ltd.
Exhibit 179: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 180: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 181: Sun Pharmaceutical Industries Ltd. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 182: Inclusions checklist
Exhibit 183: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 184: Currency conversion rates for US$
13.4 Research methodology
Exhibit 185: Research methodology
Exhibit 186: Validation techniques employed for market sizing
Exhibit 187: Information sources
13.5 List of abbreviations
Exhibit 188: List of abbreviations